Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

Articles in Press

Patrick M. Brunner

, 

Jonathan I. Silverberg

, 

Emma Guttman-Yassky

, 

Amy S. PallerPress enter key for correspondence informationPress enter key to Email the author

, 

Kenji Kabashima

, 

Masayuki Amagai

, 

Thomas A. Luger

, 

Mette Deleuran

, 

Thomas Werfel

, 

Kilian Eyerich

, 

Georg Stingl

, Councilors of the International Eczema Council

corrected proof published online XXX

Open Access

Article Info

• Abstract

• Full Text
• References
• Supplemental Materials

Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections.

Specific Antibodies for the Detection of Alternaria Allergens and the Identification of Cross-Reactive Antigens in Other Fungi

Int Arch Allergy Immunol 2016;170:269-278

(DOI:10.1159/000449415)

Open Access

Twaroch T.E.a · Curin M.a · Sterflinger K.b · Focke-Tejkl M.a · Swoboda I.a ·Valenta R.a

aChristian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, and bDepartment for Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria

Abstract:

Background: The mould Alternaria alternata is an important source of respiratory allergens. A. alternata extracts show great variations regarding allergenic potency. The aim of this study was to generate antibody probes specific for important Alternaria allergens and to use them to study allergen expression, depending on different culture conditions, as well as to search for cross-reactive allergens in other mould species. Methods: Synthetic peptides from antigenic regions of A. alternataallergens (Alt a 1, Alt a 2, Alt a 3, Alt a 6 and Alt a 8) were used to raise highly specific rabbit antibodies.

Effect of educational and electronic medical record interventions on food allergy management

• Allergy Asthma Proc
• PMC5013233

Allergy and Asthma Proceedings

Allergy Asthma Proc. 2016 Sep-Oct; 37(5): 404–408.

doi:  10.2500/aap.2016.37.3970

PMCID: PMC5013233

Ari Zelig, M.D.,1 Ilana Harwayne-Gidansky, M.D.,2 Allison Gault, M.D.,3 and Julie Wang, M.D.3

Author information ► Copyright and License information ►

Abstract

Background:

The growing prevalence of food allergies indicates a responsibility among primary care providers to ensure that their patients receive accurate diagnosis and management.

Late‐Onset Asthma Predicts Cardiovascular Disease Events: The Wisconsin Sleep Cohort

• 
   Am Heart Assoc. 2016; 5: e003448doi: 10.1161/JAHA.116.003448
• Original Research - Epidemiology

1. Matthew C. Tattersall, DO, MS¹; 
2. Jodi H. Barnet, MS²; 
3. Claudia E. Korcarz, DVM¹;
4. Erika W. Hagen, PhD²; 
5. Paul E. Peppard, PhD²; 
6. James H. Stein, MD, FAHA*,¹

+Author Affiliations

1. ¹Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
2. ²Department of Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI

Abstract

Background Asthma is a heterogeneous syndrome with different clinical subtypes that is associated with an increased risk for cardiovascular disease (CVD). We hypothesized that the late‐onset subtype of asthma is associated with a higher risk of incident CVD.

Urine metabolome profiling of immune-mediated inflammatory diseases

BMC Medicine

RESEARCH ARTICLE

 

OPEN ACCESS

 

OPEN PEER REVIEW

• Arnald Alonso,
• Antonio JuliàEmail authorView ORCID ID profile,
• Maria Vinaixa,
• Eugeni Domènech,
• Antonio Fernández-Nebro,
• Juan D. Cañete,
• Carlos Ferrándiz,
• Jesús Tornero,
• Javier P. Gisbert,
• Pilar Nos,
• Ana Gutiérrez Casbas,
• Lluís Puig,
• Isidoro González-Álvaro,
• José A. Pinto-Tasende,
• Ricardo Blanco,
• Miguel A. Rodríguez,
• Antoni Beltran,
• Xavier Correig,
• Sara MarsalEmail author and
• for the IMID Consortium

BMC Medicine201614:133

DOI: 10.1186/s12916-016-0681-8

©  The Author(s). 2016

Open Peer Review reports

Abstract

Background

Immune-mediated inflammatory diseases (IMIDs) are a group of complex and prevalent diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn’s disease, and ulcerative colitis.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope

Open Access  Review Article 

Arch Toxicol (2016). doi:10.1007/s00204-016-1876-7

• Arathi KizhedathEmail author
• Simon Wilkinson
• Jarka Glassey

Abstract

Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects.

Mast cell desensitization inhibits calcium flux and aberrantly remodels actin

J Clin Invest. 2016. doi:10.1172/JCI87492.

View: Text | PDF

W.X. Gladys Ang,1 Alison M. Church,2 Mike Kulis,3 Hae Woong Choi,4 A. Wesley Burks,3and Soman N. Abraham1,4,5,6

First published September 26, 2016 - More info

Research Article Immunology

Abstract

Rush desensitization (DS) is a widely used and effective clinical strategy for the rapid inhibition of IgE-mediated anaphylactic responses. However, the cellular targets and underlying mechanisms behind this process remain unclear. Recent studies have implicated mast cells (MCs) as the primary target cells for DS. Here, we developed a murine model of passive anaphylaxis with demonstrated MC involvement and an in vitro assay to evaluate the effect of DS on MCs.

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

• Journal List
• Data Brief
• v.9; 2016 Dec
• PMC5021787

Data Brief. 2016 Dec; 9: 199–205.

Published online 2016 Aug 29. doi:  10.1016/j.dib.2016.08.039

PMCID: PMC5021787

Veit J. Erpenbeck,a,⁎ Todor A. Popov,b David Miller,c Steven F. Weinstein,d Sheldon Spector,e Baldur Magnusson,aWande Osuntokun,f Paul Goldsmith,f Markus Weiss,a and Jutta Beierg

Author information ► Article notes ► Copyright and License information ►

Abstract

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients.

Asthma-related deaths

Multidisciplinary Respiratory Medicine

REVIEW

 

OPEN ACCESS

• Gennaro D’AmatoEmail author,
• Carolina Vitale,
• Antonio Molino,
• Anna Stanziola,
• Alessandro Sanduzzi,
• Alessandro Vatrella,
• Mauro Mormile,
• Maurizia Lanza,
• Giovanna Calabrese,
• Leonardo Antonicelli and
• Maria D’Amato

Multidisciplinary Respiratory Medicine201611:37

DOI: 10.1186/s40248-016-0073-0

Abstract

Despite major advances in the treatment of asthma and the development of several asthma guidelines, people still die of asthma currently. According to WHO estimates, approximately 250,000 people die prematurely each year from asthma. Trends of asthma mortality rates vary very widely across countries, age and ethnic groups. Several risk factors have been associated with asthma mortality, including a history of near-fatal asthma requiring intubation and mechanical ventilation, hospitalization or emergency care visit for asthma in the past year, currently using or having recently stopped using oral corticosteroids (a marker of event severity), not currently using inhaled corticosteroids, a history of psychiatric disease or psychosocial problems, poor adherence with asthma medications and/or poor adherence with (or lack of) a written asthma action plan, food allergy in a patient with asthma.

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients

Respiratory Research

RESEARCH

 

OPEN ACCESS

• Thomas SouthworthEmail author,
• Jonathan Plumb,
• Vandana Gupta,
• James Pearson,
• Isabel Ramis,
• Martin D. Lehner,
• Montserrat Miralpeix and
• Dave Singh

Respiratory Research201617:124

DOI: 10.1186/s12931-016-0436-2

Abstract

Background

Phosphatidylinositol 3-kinase delta (PI3Kδ) and Janus-activated kinases (JAK) are both novel anti-inflammatory targets in asthma that affect lymphocyte activation. We have investigated the anti-inflammatory effects of PI3Kδ and JAK inhibition on cytokine release from asthma bronchoalveolar lavage (BAL) cells and T-cell activation, and measured lung PI3Kδ and JAK signalling pathway expression.

Glial Cells are Involved in Itch Processing

Acta Derm Venereol 2016; XX: XX–XX.

DOI: 10.2340/00015555-2366

Hjalte H. Andersen, Lars Arendt-Nielsen and Parisa Gazerani*

SMI®, Department of Health Science and Technology, School of Medicine, Aalborg University, Denmark

Recent discoveries in itch neurophysiology include itch-selective neuronal pathways, the clinically relevant non-histaminergic pathway, and elucidation of the notable similarities and differences between itch and pain. Potential involvement of glial cells in itch processing and the possibility of glial modulation of chronic itch have recently been identified, similarly to the established glial modulation of pain processing.